Skip to main content

Table 2 Efficacy of case group and control group

From: Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study

Groups

Cases

tpCR,n(%)

bpCR, n(%)

ORR, n(%)

CR, n(%)

PR, n(%)

SD, n(%)

Total

138

68(49.28)

75(54.35)

134(97.10)

29(21.01)

105(76.09)

4(2.90)

Case

55

35(63.64)

38(69.09)

55(100.00)

15(27.27)

40(72.73)

0(0.00)

Control

83

33(39.76)

37(44.58)

79(95.18)

14(16.87)

65(78.31)

4(4.82)

χ2

 

7.545

8.011

1.286

2.158

0.567

1.286

P

 

0.006

0.005

0.257

0.142

0.451

0.257

  1. Case group Pyrotinib + EC-TH, Control group EC-TH; tpCR total pathologic complete response, bpCR breast pathologic complete response, ORR overall response rate, CR complete response, PR partial response, SD stable disease